紫杉醇联合奥沙利铂治疗中晚期宫颈癌患者的临床疗效

Clinical efficacy of paclitaxel combined with oxaliplatin in the treatment of patients with advanced cervical cancer

目的探讨紫杉醇联合奥沙利铂治疗中晚期宫颈癌患者的临床疗效。方法根据治疗药物的不同将109例中晚期宫颈癌患者分为观察组(n=58,紫杉醇联合奥沙利铂治疗)和对照组(n=51,紫杉醇联合顺铂治疗)。比较两组患者的近期疗效、免疫功能指标(CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))及预后。结果观察组患者的总有效率高于对照组患者,差异有统计学意义(P﹤0.05)。治疗后,两组患者的CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者的CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的1年生存率比较,差异无统计学意义(P﹥0.05)。观察组患者的3年生存率高于对照组,局部复发率、远处转移率均低于对照组,差异均有统计学意义(P﹤0.05)。结论紫杉醇联合奥沙利铂治疗中晚期宫颈癌的临床疗效显著,可有效改善患者的免疫功能及预后,可考虑在临床推广应用。

Objective To investigate the clinical efficacy of paclitaxel combined with oxaliplatin in the treatment of patients with advanced cervical cancer.Method A total of 109 patients with advanced cervical cancer were divided into observation group(n=58,treated with paclitaxel combined with oxaliplatin)and control group(n=51,treated with paclitaxel combined with cisplatin)according to different therapeutic drugs.The short-term effect,immune function indexes(CD4^(+),CD8^(+)levels,and CD4^(+)/CD8^(+)),and prognosis of the two groups were compared.Result The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,and the levels of CD8^(+)were lower than those before the treatment,the CD4^(+)level and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the CD8^(+)level was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).The 3-year survival rate of the observation group was higher than that of the control group,and the local recurrence rate and distant metastasis rate were lower than those of the control group,and the differences were statistically significant(P<0.05).Conclusion Paclitaxel combined with oxaliplatin has a significant clinical effect in the treatment of advanced cervical cancer.This therapy could effectively improve the immune function and prognosis of patients,so it would be considered for clinical application.